851597-46-1

Basic information

• Product Name: 3-FLUORO-4-[2-(1-PIPERIDINYL)ETHOXY]PHENYLAMINE
• Synonyms: 3-FLUORO-4-[2-(1-PIPERIDINYL)ETHOXY]PHENYLAMINE;AKOS B033600
• CAS NO: 851597-46-1
• Molecular Formula: C₁₃H₁₉FN₂O
• Molecular Weight: 238.3011632
• Mol File: 851597-46-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-FLUORO-4-[2-(1-PIPERIDINYL)ETHOXY]PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FLUORO-4-[2-(1-PIPERIDINYL)ETHOXY]PHENYLAMINE(851597-46-1)
• EPA Substance Registry System: 3-FLUORO-4-[2-(1-PIPERIDINYL)ETHOXY]PHENYLAMINE(851597-46-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 851597-46-1(Hazardous Substances Data)

Upstream product

• 403-19-0 2-fluoro-4-nitrophenol 
• 647858-37-5 methanesulfonic acid 2-(2-fluoro-4-nitro-phenoxy)-ethyl ester 
• 647858-19-3 2-(2-fluoro-4-nitrophenoxy)ethan-1-ol 
• 369-34-6 3,4-difluoronitrobenzene 
• 110-89-4 piperidine 
• 647858-40-0 1-{2-[(2-fluoro-4-nitrophenyl)oxy]ethyl}piperidine 

Downstream Products

• 647858-46-6 (R)-5-Azidomethyl-3-[3-fluoro-4-(2-piperidin-1-yl-ethoxy)-phenyl]-oxazolidin-2-one 
• 647858-49-9 (S)-5-Aminomethyl-3-[3-fluoro-4-(2-piperidin-1-yl-ethoxy)-phenyl]-oxazolidin-2-one 
• 647858-43-3 (R)-3-[3-Fluoro-4-(2-piperidin-1-yl-ethoxy)-phenyl]-5-hydroxymethyl-oxazolidin-2-one 

Relevant articles and documents

Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: Design, synthesis and 3D-QSAR studies

VEGFR-2 plays an essential role in angiogenesis and is a central target for anticancer drug discovery. In order to develop novel VEGFR-2 inhibitors, we designed and synthesized 33 biphenyl amides based on our previously reported lead compound. The biological results indicated that four compounds (18b, 20e, 20h and 20j) are potent VEGFR-2 inhibitors which are comparable to positive control. Compound 18b displayed the most potent VEGFR-2 inhibition with IC50 value of 2.02 nM. Moreover, it exhibited promising antiproliferative activity against MCF-7 and SMMC-7721 cells with IC50 values of 1.47 μM and 5.98 μM, respectively. Molecular docking and 3D-QSAR studies were also carried out. The results indicated that these biphenyl amides could serve as promising leads for further optimization as novel VEGFR-2 inhibitors.

2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors

The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.

2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES

The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula (1) and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to hydroxybenzimidazole pyrimidines or pyridines or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.

Influence of ethylene-oxy spacer group on the activity of linezolid: Synthesis of potent antibacterials possessing a thiocarbonyl group

The influence of an ethylene-oxy spacer element between the heterocycle and the aromatic ring in linezolid is reported. The introduction of such spacer group generated compounds with inferior antibacterial activity. However, the conversion of the acetamide group present in the linezolid analogues to either thiocarbamate or thioacetamide functionality restored the activity. The synthesis of linezolid analogues possessing the ethylene-oxy spacer group along with SAR studies with different heterocycles and preparation of some thiocarbonyl compounds possessing potent antibacterial property are presented.